



PRESS RELEASE

GREAT SUCCESS OF THE RIGHTS ISSUE

OFFERING 127.4% SUBSCRIBED

TOTAL RAISED: €29.3m

**COMPANY FUNDING POTENTIALLY GUARANTEED UP TO
THE EUROPEAN MARKET LAUNCH OF THE CARMAT TOTAL ARTIFICIAL HEART**

Paris, 8 August 2011

CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, announces the success of its capital increase with preferential subscription rights (PSRs) for existing shareholders which took place between 13 July and 29 July 2011.

This rights issue, managed by DEXIA SECURITIES FRANCE and BNP PARIBAS Joint Lead Managers and Bookrunners and by PORTZAMPARC as Co-Lead Manager, saw total demand for 306,488 shares (compared to a total of 240,617 offered before the triggering of the extension clause), representing over-subscription of 27.4%, or total demand of €32.5m.

Given this achievement, CARMAT's Board of Directors decided to exercise the extension clause in full, bringing the total number of shares issued to 276,709 and the total raised to €29.3m.

The exercise of irreducible preferential subscription rights covered 228,322 new shares, or 82.5% of the new shares to be issued after exercising the extension clause. Subscriptions for 78,166 shares on a reducible basis were received and will therefore be only partially satisfied by the issue of 48,387 new shares.

The rights issue was underwritten for a total of €10.5m by Truffle Capital. Given the success of the rights issue, it was not necessary to call on this commitment. The incumbent shareholders - Truffle Capital, EADS and Marie Lannelongue surgical centre - subscribed €3.5m to the capital increase.

The proceeds of this rights issue will be used to finance the conduct of clinical trials in France and in Europe, the industrialisation of the CARMAT artificial heart project, up to its launch on the European market, as well as the accelerated development of its portable external system components (batteries, connectivity, monitoring unit, etc.), with a view to having them on the market in 2013.

Thanks to the success of this rights issue, CARMAT is now one of the best capitalised European companies in the medical devices sector and can plan its strategic and industrial development with confidence.

**NOT FOR PUBLICATION, DISTRIBUTION OR DISSEMINATION, DIRECTLY OR
INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN**

Marcello Conviti, CEO of CARMAT, comments: *“We are extremely pleased with the success of this rights issue, which reflects the strong support for our project from the financial community, in spite of very difficult market conditions, and the expectations which the CARMAT project addresses. The funds raised will allow us to finance the development of our total artificial heart and its external elements through to approval for sale in Europe, and in particular will help fund initial clinical trials in man, which are expected to begin at the end of 2011, after approval from the regulatory authorities. We would like to thank all of our core shareholders and the thousands of individual shareholders for their commitment, their confidence, their loyalty and their support, which allowed this rights issue to be such a success and will allow us to make rapid and concrete progress on our unique project.”*

Issuance, settlement and delivery, and commencement of trading in new shares on NYSE-Alternext Paris will take place on 10 August 2011. From 10 August 2011, the total number of shares constituting CARMAT’s capital will thus be increased to 4,126,595.

Availability of prospectus

Copies of the prospectus, consisting of the Reference Document registered under number R. 11-017 on 27 April by the Autorité des Marchés Financiers and the Issue Document registered under n°11-308 on 11 July 2011, are available without charge and on demand from CARMAT, Direction Administrative et financière, 36 avenue de l’Europe – CS 40533 – 78941 Vélizy Villacoublay Cedex and on the websites of the Autorité des Marchés Financiers (www.amf-france.org) and CARMAT (www.carmatsa.com).

Members of the public are invited to consider the sections headed “Risk Factors” in the prospectus as approved by the Autorité des Marchés Financiers. These risk factors are described in Section 4 of the Reference Document and Section 2 in the Issue Document.

About CARMAT: CARMAT, the world’s most advanced total artificial heart

The only credible response for all cases of end-stage heart failure - a true public health issue. CARMAT’s ultimate aim is to provide a response to a major public health issue associated with cardiovascular disease, the world’s leading cause of death: heart failure. This disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from end-stage heart failure.

The result of combining two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves - most widely used worldwide - and the technological expertise of EADS, a global aerospace leader.

Imitating the natural heart. Given its size and weight, the choice of structural materials and its innovative physiological functions, CARMAT’s total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit tens of thousands of patients a year – with no risk of rejection and providing them with unparalleled quality of life.

A project leader acknowledged at the European level: with the backing of the European Commission, CARMAT has received the largest grant-in-aid (a total of €33m) made to an SME by OSEO (the French state innovation agency).

Strongly committed, prestigious founders and shareholders: Truffle Capital (the leading European venture capital firm), EADS, the Foundation Alain Carpentier and thousands of institutional and individual shareholders have placed their trust in CARMAT.

For more information, visit www.carmatsa.com

**NOT FOR PUBLICATION, DISTRIBUTION OR DISSEMINATION, DIRECTLY OR
INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN**



CARMAT

Marcello Conviti
CEO

Patrick Coulombier
COO

Valerie Leroy
Marketing and Investor
Relations Director

Tel. : +33 1 39 456450
investors@carmatsa.com

DEXIA SECURITIES
Listing Sponsor

Jean-Michel Cabriot
Head of Corporate Finance
Tel. : +33 1 56 28 52 68
Jean-michel.cabriot@dexia-securities.fr

NewCap.

Financial communication
and investor relations

Axelle Vuillermet / Emmanuel Huynh
Tel.: +33 1 44 71 94 94
carmat@newcap.fr



Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**

Alize RP

Press relations

Caroline Carmagnol
+33 6 64 18 99 59
caroline@alizerp.com

Disclaimer

This press release and the information contained herein does not constitute or form part of, and should not be constituted as, an offer or invitation to sell or subscribe for, or a solicitation of any offer or invitation to acquire, dispose of or subscribe for, shares in Carmat ("the Company") in any country. The publication of this press release in certain countries may violate applicable regulations. With respect to the member states of the European Economic Area which have implemented the Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003 (the "Prospectus Directive"), other than France, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member state (other than France). As a result, the securities may not and will not be offered in any relevant member state (other than France) except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member state, or under any other circumstances which do not require the publication by Carmat of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member state. The information contained therein does not constitute an offer for securities in the United States, Canada, Australia or Japan or in any other jurisdiction. This press release should not be published, transmitted or distributed, directly or indirectly, into the United States, Canada, Australia or Japan. This press release is not an offer for sale or a solicitation of offers to purchase CARMAT securities in the United States. The securities of CARMAT may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. CARMAT does not intend to register any portion of the offering in the United States or to conduct a public offering of securities in the United States. This press release does not constitute an invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000 and is for distribution only to persons who (A) are outside the United Kingdom, or (B) are qualified investors as described in section 86(7) of the Financial Services and Markets Act 2000 (being persons falling within Article 2.1(e)(i), (ii) or (iii) of Directive 2003/71/EC) and (i) have professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), or (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order, or (iii) to whom it may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). This press release is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons. This press release contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence registered with the Autorité des Marchés Financiers under number R.11-017 on 27 April 2011 and the Note d'Opération that was approved by the Autorité des Marchés Financiers on 11 July 2011, changes in economic conditions, the financial markets or the markets in which CARMAT operates.